GlassScriptPhysician profile
Daniel J Mullins
NPI 1205063849
$2,732.19
in general payments reported to CMS, 2019-2025
21 companies · $323 in 2025
The $323 reported for 2025 was less than what a typical Colon & Rectal Surgery provider received nationally (typical 2025 total: $317).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,342 · 2020: $13.64 · 2021: $108 · 2022: $206 · 2023: $265 · 2024: $475 · 2025: $323.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,063.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,063.42 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $1,342.52 | 2019-2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $331.12 | 2020-2025 | Entyvio, Gattex |
| Celgene Corporation | $161.51 | 2021-2023 | Zeposia |
| Abbvie INC. | $149.91 | 2023-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $123.62 | 2021-2024 | Xifaxan, Trulance |
| Thd America, INC. | $105.00 | 2025 | |
| Janssen Biotech, INC. | $89.74 | 2023-2025 | Stelara, Tremfya |
| Allergan, INC. | $80.88 | 2022 | |
| Shire North American Group INC | $45.61 | 2019 | |
| Intercept Pharmaceuticals, INC. | $42.59 | 2024 | |
| Celltrion USA INC. | $36.54 | 2024 | Zymfentra |
| Madrigal Pharmaceuticals | $29.40 | 2024 | Resmetirom |
| Kci USA, INC. | $28.59 | 2019 | |
| Covidien LP | $26.84 | 2019 | |
| Stryker Corporation | $25.95 | 2021 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exact Sciences Corporation | $23.02 | 2025 | The Cologuard Plus Collection Kit |
| Olympus America INC. | $20.58 | 2023 | Single Use Electrosurgical Snare Sd-400 |
| Ethicon US, LLC | $19.61 | 2019 | |
| Axonics, INC. | $19.30 | 2023 | Axonics |
| Masimo Corporation | $17.00 | 2021 | |
| Davol INC. | $12.86 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Mullins listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.